ProcartaPlex™ Human Immuno-Oncology Checkpoint Panel 1, 14plex
Invitrogen™

ProcartaPlex™ Human Immuno-Oncology Checkpoint Panel 1, 14plex

Le panneau 1 Human Immuno-Oncology Checkpoint 14-Plex ProcartaPlex permet la recherche sur le cancer en analysant 14 cibles protéiques à l’aide de la technologie Luminex xMAP.
Have Questions?
RéférenceQuantité
EPX14A-15803-90196 dosages
Référence EPX14A-15803-901
Prix (EUR)
3 700,00
Each
Quantité:
96 dosages
Prix (EUR)
3 700,00
Each

Le panneau 1 Human Immuno-Oncology Checkpoint 14-Plex ProcartaPlex permet la recherche sur le cancer en analysant 14 cibles protéiques à l’aide de la technologie Luminex xMAP. Ce panel permet la détection simultanée des formes solubles de protéines qui jouent un rôle crucial dans la régulation des lymphocytes T, conduisant soit à l’épuisement soit à la stimulation des lymphocytes T, modifiant ainsi la réponse immunitaire antitumorale. L’analyse de ces biomarqueurs solubles pourrait aider à faire la lumière sur la biologie des voies. Il complète le panneau 2 Immuno-Oncology Checkpoint 14-Plex ProcartaPlex (réf EPX140-15815-901) et le panel 3 Immuno-Oncology Checkpoint 9-Plex ProcartaPlex (réf. EPX090-15820-901) qui fournit 23 cibles protéiques supplémentaires dans le même domaine de recherche.

Les panneaux préconfigurés ProcartaPlex sont largement testés pour la combinabilité, l’interférence et la réactivité croisée des analyses afin de fournir le plus haut niveau de validation et de précision. Tous les panneaux ProcartaPlex sont fournis avec les réactifs nécessaires pour effectuer le dosage.

Liste de cibles [région de microbille] :
Stimulation immunitaire : CD27 [27], CD28 [15], CD137 (4-1BB) [26], GITR [57], HVEM [36]
Inhibiteur immunitaire : BTLA [52], CD80 [61], CD152 (CTLA4) [33], IDO [46], LAG-3 [47], PD-1 [65], PD-L1 [66], PD-L2 [67], TIM-3 [14]

À propos des dosages ProcartaPlex pour la plateforme Luminex
Les immunodosages ProcartaPlex sont basés sur les principes d’un ELISA de type sandwich, avec l’utilisation de deux anticorps hautement spécifiques se liant à différents épitopes d’une protéine pour quantifier simultanément toutes les cibles protéiques à l’aide d’un instrument Luminex. Les dosages multiplex ProcartaPlex nécessitent seulement seulement 25 μl de plasma ou de sérum, ou 50 μl de surnageant de culture cellulaire, et seulement quatre heures pour obtenir les résultats analysés.

Caractéristiques :
• Résultats reproductibles et fiables — validés en panneau selon la norme la plus élevée de l’industrie, avec des tests de combinabilité des cibles protéiques et de réactivité croisée
• Plus de résultats par échantillonneur — permet de réaliser simultanément plusieurs cibles protéiques dans un seul échantillon de 25 – 50 μl
• Plate-forme de multiplexage à haute référence avec la technologie bien établie Luminex, pour la détection et la quantification des protéines

Les dosages ProcartaPlex utilisent Luminex xMAP (profilage multianalyte) Technologie pour la détection et la quantification simultanées de jusqu’à 80 cibles protéiques dans un seul échantillon de 25–50 μl — de plasma, de sérum, de surnageant de culture cellulaire et d’autres liquides corporels.

Les microbilles Luminex dans le dosage ProcartaPlex sont colorées en interne avec des proportions précises de fluorophores rouges et IR pour créer des signatures uniques de façon spectrale qui peuvent être identifiées par les systèmes de détection Luminex xMAP (par exemple Luminex 200, FLEXMAP 3D et MAGPIX). Comme le dosage ELISA sandwich, le dosage ProcartaPlex utilise des paires d’anticorps appariées pour identifier la protéine d’intérêt. Dans un dosage multiplexé, chaque microbille unique de façon spectrale est marquée avec des anticorps spécifiques pour une seule protéine cible et les protéines liées sont identifiées avec des anticorps biotinylés et de la streptavidine–R-phycoérythrine (RPE). La conjugaison d’anticorps spécifiques d'une protéine à une microbille distincte permet d’analyser plusieurs cibles dans un seul puits.

La différence la plus significative entre un dosage ProcartaPlex et un dosage ELISA est que l’anticorps de capture du dosage ProcartaPlex est conjugué à une microbille et n’est pas adsorbé par un des puits de la microplaque. Ainsi, les réactifs de dosage ProcartaPlex flottent librement dans la solution.

Usage exclusivement réservé à la recherche. Ne pas utiliser pour des procédures de diagnostic.
Spécifications
Plage de dosageVoir le certificat d’analyse
Sensibilité du dosageVoir le certificat d’analyse
Méthode de détectionFluorescent
À utiliser avec (équipement)Instruments Luminex™
FormatKit multiplex
Gamme de produitsProcartaPlex
Type d’échantillonSérum, plasma, surnageants de culture cellulaire (SCC), Plasma, Cell Culture Supernatants
Volume d’échantillonSérum, plasma : 25 μl, surnageant de culture cellulaire : 50 μlitres
Conditions d’expéditionGlace humide
CombinabilityCombinable
Type de produitPanneau multiplex
Quantité96 dosages
Research AreaImmunology, Oncology
EspècesHumaine
Unit SizeEach
Contenu et stockage
  • 2 flacons de mélange étalon humain L (lyophilisé)
  • 1 flacon de mélange de microbilles de capture (1X)
  • 1 flacon de mélange d’anticorps de détection biotinylé (50 X)
  • 1 flacon de tampon de lecture (1X)
  • 1 flacon de tampon de lavage (10X)
  • 1 flacon de streptavidine-PE (1X)
  • 1 flacon de tampon de dosage universel (1X)
  • 1 flacon de diluant d’anticorps de détection (1X)
  • Barrettes de 8 tubes
  • Film adhésif
  • Plaque 96 puits à fond plat, noire
  • Stocker de 2°C à 8°C

Foire aux questions (FAQ)

What is the size of the Luminex beads you currently use?

The beads used in our Luminex instrument-compatible ProcartaPlex and QuantiGene Plex assays are 6.5 micron superparamagnetic beads.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

I am interested in performing Luminex assays using BioSource kits, and I have a Luminex xMAP system. Besides the kits and system, what other reagents and equipment will I need?

The following is a list of general lab supplies that are required for running BioSource immunoassays on the Luminex xMAP system:
1) Sonicating water bath
2) Orbital shaker
3) Vortexer
4) Repeating and/or multi-channel pipetter (not required, but recommended)
5) Calibrated adjustable precision pipettes, with disposable plastic tips
6) Glass/plastic tubes and racks for preparing reagents
7) Graduated cylinder and container for preparing wash solution
8) Aluminum foil
9) Deionized or distilled water.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Do the Luminex beads require special care in handling?

The Luminex beads should be protected from light because they are susceptible to photobleaching. We recommend protecting the beads by keeping containers covered with aluminum foil during all incubation steps, and exercising care during handling. The beads should not be frozen, subjected to excessive heat, or exposed to organic solvents.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Why would the Luminex acquisition software display "Sample Empty" messages during analysis?

(1) The user did not properly aliquot the diluted beads, such that no beads were actually added to the wells (make sure that the bead concentrates are sonicated and vortexed well, then check the pipet tip to ensure that air bubbles were not drawn up)
(2) The user missed loading diluted beads to some wells, which is likely since the small volume is clear and difficult to visualize in the clear plastic plate (we have now addressed this customer difficulty by coloring each of the Buffer Reagent Kit components)
(3) The user applied too much vacuum pressure at some point during the wash steps, or allowed the pressure to spike even once, such that the filter membrane tore in a few wells releasing the beads (make sure that the vacuum manifold pressure is kept below 5mm/in Hg, depending on their system -- a good rule of thumb is that it should take a full 3-second count to GENTLY empty the wells of 200uL)
(4) The user did not properly sonicate and vortex the beads prior to dilution, such that the percent of bead aggregation was high and the instrument was unable to find enough single beads to meet the events/bead value designated by the customer (make sure that the Bead Concentrate tube is put into the waterbath all the way to the cap, since the tube is hollow until the top third)
(5) The user lost beads by shaking the plate too aggressively or handling it improperly (make sure that the orbital shaker is set to a speed that allows for maximum vortex in the wells without spillage)
(6) The user exposed the beads to an excess of light during storage or running of the assay, such that some but not all of the beads were photobleached and therefore falling outside the acceptable range for each bead region (make sure that the plate is covered on the top/sides with foil throughout the assay, away from Windows and spotlights, and that the bead component of the kits is stored in the dark)*
(7) There was a clog in the sample needle, such that the instrument was unable to take up enough sample to meet the number of events requested per bead region (suggest that the user follow the manual instructions for dislodging a clog, which include several Back Flush steps and may require removal of the needle for sonication with probe alignment).

* Some of the older Antibody Bead Kits still have clear plastic tops instead of black ones. In cases where customers store kits in lit refrigerators, or keep them open on the lab bench, even a few hours of light exposure is enough to photobleach beads. It is important to note, in general, that higher number bead regions are more susceptible to photobleaching. In order to draw conclusions about the source of the difficulty, we would ask to see the data, specifically the Masterplex QT file, which would enable us to examine the pattern of "Sample Empty" occurrences in addition to the bead counts per well.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

What are the Luminex beads made of?

The beads are made of polystyrene.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Citations et références (10)

Citations et références
Abstract
Immune monitoring of trabectedin therapy in refractory soft tissue sarcoma patients - the IMMUNYON study.
Authors:Rodrigues-Santos P,Almeida JS,Sousa LM,Couceiro P,Martinho A,Rodrigues J,Fonseca R,Santos-Rosa M,Freitas-Tavares P,Casanova JM
Journal:Frontiers in immunology
PubMed ID:40007535
Soft tissue sarcomas (STS) encompass over 50 histologic subtypes, representing more than 1% of solid tumors. Standard treatments include surgical resection and therapies such as anthracyclines or trabectedin for advanced cases, though challenges persist due to the tumor microenvironment’s complexity and limited immune profiling data. This study evaluates Trabectedin therapy ... More
Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.
Authors:J. Gorgulho et al.
Journal:British Journal of Cancer
PubMed ID:38233492
The search for biomarkers to identify suitable candidates for immune checkpoint inhibitor (ICI) therapy remains ongoing. We evaluate how soluble levels of the next generation immune checkpoint Lymphocyte Activation Gene-3 (sLAG-3) and its association with circulating T lymphocyte subsets could pose as a novel biomarker to predict outcome to ICI ... More
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.
Authors:Aref AR, Campisi M, Ivanova E, Portell A, Larios D, Piel BP, Mathur N, Zhou C, Coakley RV, Bartels A, Bowden M, Herbert Z, Hill S, Gilhooley S, Carter J, Cañadas I, Thai TC, Kitajima S, Chiono V, Paweletz CP, Barbie DA, Kamm RD, Jenkins RW
Journal:Lab Chip
PubMed ID:30183789
Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several microdevices are being developed specifically for clinical use to test novel cancer therapeutics. To be effective, these platforms need to replicate the continuous interactions that exist between tumor cells and non-tumor cell elements of the tumor microenvironment ... More
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Authors:Rolfes V, Idel C, Pries R, Plötze-Martin K, Habermann J, Gemoll T, Bohnet S, Latz E, Ribbat-Idel J, Franklin BS, Wollenberg B
Journal:Oncotarget
PubMed ID:29937998
Cancer immunotherapy has been revolutionised by drugs that enhance the ability of the immune system to detect and fight tumors. Immune checkpoint therapies that target the programmed death-1 receptor (PD-1), or its ligand (PD-L1) have shown unprecedented rates of durable clinical responses in patients with various cancer types. However, there ... More
Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Authors:Wang Q, Zhang J, Tu H, Liang D, Chang DW, Ye Y, Wu X
Journal:J Immunother Cancer
PubMed ID:31783776
Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. With the exception of a few candidate biomarkers, the prognostic role of soluble immune checkpoint-related proteins in clear cell renal cell cancer (ccRCC) patients is largely uninvestigated. ... More